ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 569,13
-0,83%
Dow Jones
40 211,72
0,53%
DAX
18 470,78
-0,70%
Brent Oil
83,69
-0,77%
Bitcoin
63 001,52
-2,85%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PureTech Health PLC (PRTC)

  7. PureTech Health PLC (PRTC) Actualités

PRTC

PureTech Health (PRTC)

PureTech Health PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRTC
DateHeureSourceTitreSymboleSociété
11/10/202313h00Business WirePureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual MeetingNASDAQ:PRTCPureTech Health PLC
04/10/202313h05Business WirePureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track DesignationNASDAQ:PRTCPureTech Health PLC
28/09/202313h38Business WireKarXT, invented at PureTech, submitted for FDA Approval in SchizophreniaNASDAQ:PRTCPureTech Health PLC
27/09/202308h05Business WirePureTech Announces the Appointment of Robert Lyne as Chief Portfolio OfficerNASDAQ:PRTCPureTech Health PLC
06/09/202322h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
29/08/202308h00Business WirePureTech Health plc – Half-Year ReportNASDAQ:PRTCPureTech Health PLC
22/08/202308h00Business WirePureTech Health: Notice of Half-Yearly ResultsNASDAQ:PRTCPureTech Health PLC
01/08/202313h00Business WirePureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia SyndromeNASDAQ:PRTCPureTech Health PLC
21/06/202313h00Business WirePureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety DisordersNASDAQ:PRTCPureTech Health PLC
13/06/202318h40Business WireResults of PureTech's Annual General MeetingNASDAQ:PRTCPureTech Health PLC
12/06/202322h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PRTCPureTech Health PLC
24/05/202313h00Business Wire PureTech to Present at the Jefferies Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
09/05/202308h00Business WirePureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease WeekNASDAQ:PRTCPureTech Health PLC
04/05/202308h00Business WirePureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based TherapeuticNASDAQ:PRTCPureTech Health PLC
28/04/202313h29Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PRTCPureTech Health PLC
28/04/202308h00Business WirePureTech Announces Annual Results for Year Ended December 31, 2022NASDAQ:PRTCPureTech Health PLC
25/04/202312h50Business WirePureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia TherapiesNASDAQ:PRTCPureTech Health PLC
17/04/202313h05Business WirePureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMIDNASDAQ:PRTCPureTech Health PLC
13/04/202308h00Business WirePureTech Health: Notice of ResultsNASDAQ:PRTCPureTech Health PLC
23/03/202312h00GlobeNewswire Inc.Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 MillionNASDAQ:PRTCPureTech Health PLC
23/03/202308h00Business WirePureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 MillionNASDAQ:PRTCPureTech Health PLC
01/03/202313h00Business WirePureTech to Present at the Barclays Global Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
27/02/202315h05Business WirePureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)NASDAQ:PRTCPureTech Health PLC
14/02/202313h00Business WirePureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum DepressionNASDAQ:PRTCPureTech Health PLC
10/02/202312h10Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NASDAQ:PRTCPureTech Health PLC
01/02/202313h00Business WirePureTech to Present at the SVB Securities Global Biopharma ConferenceNASDAQ:PRTCPureTech Health PLC
22/12/202208h00Business WirePureTech Provides End of Year Report on Key ProgressNASDAQ:PRTCPureTech Health PLC
19/12/202213h00Business WirePureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy VolunteersNASDAQ:PRTCPureTech Health PLC
13/12/202213h00Business WirePureTech to Present at 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
12/12/202215h00Business WirePureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual MeetingNASDAQ:PRTCPureTech Health PLC
 Showing the most relevant articles for your search:NASDAQ:PRTC

Dernières Valeurs Consultées

BIT
P235T7
NLBNPIT235T7 20240822 3.4
USOTC
KANP
Kaanapali Land (PK)
NYSE
ARR-C
ARMOUR Residential REIT
BIT
P251A4
NLBNPIT251A4 20250620 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés